Strohmenger H U, Lindner K H, Keller A, Lindner I M, Pfenninger E, Bothner U
Department of Anesthesiology and Critical Care Medicine, University of Ulm, Germany.
Crit Care Med. 1996 Aug;24(8):1360-5. doi: 10.1097/00003246-199608000-00015.
To assess the effects of graded doses of vasopressin vs. saline on median fibrillation frequency and defibrillation success in a porcine model of cardiopulmonary resuscitation.
Prospective, randomized, controlled trial.
Animal laboratory in a university medical center.
Twenty-eight domestic pigs (body weight between 26 and 31 kg), aged 12 to 14 wks.
After 4 mins of ventricular fibrillation and 3 mins of closed-chest cardiopulmonary resuscitation, the animals were allocated to receive either 0.2 U/kg of vasopressin (n = 7), 0.4 U/kg of vasopressin (n = 7), 0.8 U/kg of vasopressin (n = 7), or 10 mL of saline (n = 7, control group). Using radiolabeled microspheres, myocardial blood flow rates during cardiopulmonary resuscitation-before drug administration and 90 secs and 5 mins after drug administration-were as follows in the four groups (mean +/- SEM): 18.8 +/- 0.9, 17.2 +/- 1.1, and 14.6 +/- 1.4 mL/min/100 g in the control group; 17.8 +/- 2.2, 49.6 +/- 6.3 (p < .01 vs. control group), and 29.4 +/- 3.1 mL/min/100 g (p < .05 vs. control group) in the group receiving 0.2 U/kg of vasopressin; 17.1 +/- 1.0, 52.4 +/- 7.5 (p < .01 vs. control group), and 52.2 +/- 5.8 mL/min/100 g (p < .001 vs. control group) in the group receiving 0.4 U/kg of vasopressin; and 18.1 +/- 1.6, 94.9 +/- 9.2 (p < .001 vs. control group), and 57.2 +/- 6.3 mL/min/100 g (p < .001 vs. control group) in the group receiving 0.8 U/kg of vasopressin. Using spectral analysis, median frequencies of ventricular fibrillation-before drug administration and 90 secs and 5 mins after drug administration-were as follows in the four groups: 9.6 +/- 0.4, 8.5 +/- 0.8, and 7.2 +/- 1.0 Hz in the control group; 9.7 +/- 0.5, 12.9 +/- 0.8 (p < .01 vs. control group), and 12.7 +/- 0.8 Hz (p < .001 vs. control group) in the group receiving 0.2 U/kg of vasopressin; 10.3 +/- 0.2, 12.7 +/- 0.9 (p < .01 vs. control group), and 12.8 +/- 0.7 Hz (p < .001 vs. control group) in the group receiving 0.4 U/kg of vasopressin; and 10.0 +/- 0.9, 14.1 +/- 0.9 (p < .001 vs. control group), and 12.5 +/- 0.9 Hz (p < .001 vs. control group) in the group receiving 0.8 U/kg of vasopressin at the same points in time. Median frequency before the first defibrillation attempt was 12.3 +/- 0.4 Hz in the resuscitated animals (n = 19) and 8.2 +/- 1.2 Hz in the nonresuscitated animals (n = 9) (p < .001).
This study contributes to the characterization of the effect of increasing global myocardial blood flow on median fibrillation frequency after administration of graded doses of vasopressin in a porcine model of ventricular fibrillation. Interventions such as vasopressor treatment that increase fibrillation frequency improve the chance of successful defibrillation.
在猪心肺复苏模型中,评估不同剂量血管加压素与生理盐水对中位颤动频率及除颤成功率的影响。
前瞻性、随机、对照试验。
大学医学中心的动物实验室。
28头家猪(体重26至31千克),年龄12至14周。
在心室颤动4分钟及闭胸心肺复苏3分钟后,将动物分为四组,分别接受0.2 U/kg血管加压素(n = 7)、0.4 U/kg血管加压素(n = 7)、0.8 U/kg血管加压素(n = 7)或10 mL生理盐水(n = 7,对照组)。使用放射性微球,四组在心肺复苏期间(给药前、给药后90秒和5分钟)的心肌血流速率如下(均值±标准误):对照组为18.8±0.9、17.2±1.1和14.6±1.4 mL/分钟/100克;接受0.2 U/kg血管加压素组为17.8±2.2、49.6±6.3(与对照组相比p <.01)和29.4±3.1 mL/分钟/100克(与对照组相比p <.05);接受0.4 U/kg血管加压素组为17.1±1.0、52.4±7.5(与对照组相比p <.01)和52.2±5.8 mL/分钟/100克(与对照组相比p <.001);接受0.8 U/kg血管加压素组为18.1±1.6、94.9±9.2(与对照组相比p <.001)和57.2±6.3 mL/分钟/100克(与对照组相比p <.001)。使用频谱分析,四组在给药前、给药后90秒和5分钟时的心室颤动中位频率如下:对照组为9.6±0.4、8.5±0.8和7.2±1.0 Hz;接受0.2 U/kg血管加压素组为9.7±0.5、12.9±0.8(与对照组相比p <.01)和12.7±0.8 Hz(与对照组相比p <.001);接受0.4 U/kg血管加压素组为10.3±0.2、12.7±0.9(与对照组相比p <.01)和12.8±0.7 Hz(与对照组相比p <.001);接受0.8 U/kg血管加压素组在相同时间点为10.0±0.9、14.1±0.9(与对照组相比p <.001)和12.5±0.9 Hz(与对照组相比p <.001)。首次除颤尝试前,复苏动物(n = 19)的中位频率为12.3±0.4 Hz,未复苏动物(n = 9)为8.2±1.2 Hz(p <.001)。
本研究有助于明确在猪心室颤动模型中,递增剂量血管加压素给药后,增加全心肌血流量对中位颤动频率的影响特征。诸如血管升压药治疗等能增加颤动频率的干预措施可提高除颤成功率。